On November 17, 2021 La Jolla Pharmaceutical Company (Nasdaq: LJPC) reported that it will commence a share repurchase plan for up to $10 million of the Company’s common stock. Repurchases may be made from time to time at the Company’s discretion (Press release, La Jolla Pharmaceutical, NOV 17, 2021, View Source [SID1234595790]). The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The decision to repurchase shares reflects our confidence in our team and the ability to execute against our strategic initiatives for growth, which is supported by the strength of our balance sheet," said Larry Edwards, President and Chief Executive Officer of La Jolla.